Advaite

06/29/2021

BGI announces strategic US partnership with Advaite, launches diagnostics partnership forum

Collaboration between two biotech companies signals BGI’s increased focus on fostering partnerships with organizations in the diagnostics space

Collaboration between two biotech companies signals BGI’s increased focus on fostering partnerships with organizations in the diagnostics space...

01/12/2021

FDA GRANTS ADVAITE EMERGENCY USE AUTHORIZATION FOR RapCov™ Rapid COVID-19 Test.

All RapCov™ Rapid COVID-19 Test Kits are manufactured and assembled start to finish at FDA registered facilities in Southeastern Pennsylvania, and ADVAITE plans to immediately begin supplying the market with its testing kits on a national scale.

Contact:
Ph:+1(484) 842-0220
Email: bprathi@advaite.com

https://www.prnewswire.com/news-releases/fda-grants-advaite-emergency-use-authorization-for-rapcov-rapid-covid-19-test-301206323.html

/PRNewswire/ -- The U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) to one of the first U.S.-manufactured serology tests...

12/08/2020

Advaite offers COVID-19 testing for Businesses who wants to remain open during this pandemic.

We offer gold standard RT PCR based Saliva test and provide results in 24-48 hours.

Please contact us today to schedule SalivaDirect testing for your Business.

Email:bprathi@advaite.com
Phone:+1(484) 842-0220

04/09/2020

Advaite announced today that it has delivered antibody rapid test kits to Chester County Health Department. Advaite has worked to optimize its diagnostic reagent technology in developing its novel COVID-19 Rapid Antibody test kits. The RapCov Rapid COVID-19 Test is an in vitro diagnostic test for the qualitative detection of IgG or IgM antibodies to the COVID-19 virus in human whole blood fingerstick samples collected in CLIA certified laboratories and/or by healthcare workers at the point-of-care. The RapCov test provides valuable information regarding the body’s immune response to the presence of the COVID-19 virus.

/PRNewswire/ -- Advaite, an innovative biotech company focused on developing novel diagnostics, announced today that it has delivered antibody rapid test kits...

02/08/2020

Sandeep Jain, MD founder and Chief Scientific Officer of Advaite will participate in an online webinar on ocular GVHD

12/10/2019

Advaite Founder and Chief Scientific officer, Sandeep Jain, MD, and Christine Mun BS are authors on a publication that points to the potential of Neutrophil-associated proteins (Interlukin-8, or LIGHT/TNFSF14) to serve as biomarkers and heparin eye drops as treatment for ocular GVHD. These biomarkers and therapeutics are being developed by Advaite for diagnosing and treating ocular GVHD.

To investigate the role of neutrophil extracellular traps (NETs) and NET-associated proteins in the pathogenesis of oGVHD and whether dismantling of N…

12/10/2019

Advaite has entered into an exclusive license option agreement with the George Washington University with respect to the intellectual property of a novel AMES Negative HDAC6 inhibitor. Histone Deacetylases modulate a multitude of cellular processes and are part of the regulation of cellular pathways involved in anti-tumor immunologic responses.

/PRNewswire/ -- Advaite Inc., a Chicago, IL based oncology-focused biotech company developing novel therapeutics and diagnostics to help patients suffering...

05/05/2019

Advaite Founder and Chief Scientific officer, Sandeep Jain, MD, and Christine Mun BS, presented clinical data in a Special Interest Group talk and a poster highlighting the potential of LIGHT/TNFSF14 protein (ADV200) to serve as a diagnostic and monitoring biomarker at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, held on April 28 – May 2, 2019, in Vancouver, Canada. The results showed that LIGHT/TNFSF14 protein had a specificity of over 90% in diagnosing ocular GVHD. In contrast, MMP-9 test (InflammaDry) had a specificity of only 9%.

09/15/2018

Advaite Chief Scientific officer, Sandeep Jain, MD, presented pre-clinical and clinical data regarding heparin eye drops (ADV100) at the International Society for Eye Research (ISER) biennial meeting held in Belfast, Ireland on September 9 - 13, 2018.

05/03/2018

Advaite Founder and Chief Scientific officer, Sandeep Jain, MD, presented preclinical data in a poster highlighting the potential efficacy of sub-anticoagulant dose heparin (ADV100) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held April 29 – May 3, 2018, in Honolulu, Hawaii. The results highlighted the anti-inflammatory, immunosuppressive and antifibrotic actions of heparin (100 IU/ml) using preclinical in-vitro and in-vivo models.

02/10/2018

ADVAITE Founder and Chief Scientific Officer Dr. Sandeep Jain featured in UIC NEWS

Sandeep Jain is amongst the few clinical scientists in the field who have taken their research discovery from laboratory to the clinic and converted them to new therapies.

01/11/2018

ADVAITE Founder and Chief Scientific Officer Dr. Sandeep Jain Named as ‘Inventor of the Year’ by University of Illinois at Chicago Chicago, IL, December 26, 2017 ADVAITE, a clinical-stage biopharmaceutical company that is developing innovative therapeutic, diagnostic and healthcare solutions to ...

01/11/2018

ADVAITE was one of three startup companies invited to present at the Angel Venture Fair held on January 9th, 2018 in West Chester, PA. Our presentation on ADV100 and ADV200 generated substantial interest from participating investors.

06/25/2017

ADV100 is a drug that has significant anti inflammatory and anti-fibrotic actions . It thus has therapeutic potential in reducing ocular surface disease secondary to tear deficiency induced by conditions such as ocular GVHD, Stevens Jonson syndrome and Sjogrens syndrome.